Phase 2/3Completed
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over
- Sponsor
- Dermatology Specialties Limited Partnership (Industry)
- Enrolment
- 107 enrolled
- Conditions
- Facial Angiofibroma; Tuberous Sclerosis
- Interventions
- rapamycin; placebo
- Ages
- children, adults, older adults
- Registry
- NCT03826628
Full record on ClinicalTrials.gov
From the registry
The study aims to compare the safety and efficacy of two different strengths of Rapamycin cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC).
Primary outcomes
- Percentage of Participants Obtaining Successful Treatment
History
Last registry update
Results first posted
Primary completion
Started
Registered